Drug Profile


Alternative Names: Beleodaq; CLN-9; ComboBelCHOP; PDX 101; PX-105684; PXD 101

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TopoTarget
  • Developer CIMA- Universidad de Navarra; Emory University; National Cancer Institute (USA); Onxeo SA; Spectrum Pharmaceuticals; TopoTarget
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase II B cell lymphoma; Glioblastoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia; Lymphoma; Myelodysplastic syndromes; Small cell lung cancer; Solid tumours
  • Preclinical Hepatocellular carcinoma
  • No development reported Bladder cancer; Carcinoma; Colorectal cancer; Cutaneous T cell lymphoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer; Soft tissue sarcoma; Thymoma
  • Discontinued Multiple myeloma

Most Recent Events

  • 02 Oct 2017 Onxeo plans a phase I trial for Cancer (PO) in early 2019
  • 28 Sep 2017 Onxeo files for patent protection for Belinostat (PO)
  • 16 Jun 2017 National Cancer Institute completes a phase I trial in Small cell lung cancer (Late-stage disease, Combination therapy) in USA (IV) (NCT00926640)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top